Literature DB >> 15803931

Mycophenolate mofetil and neurological diseases.

P Vermersch1, T Stojkovic, J de Seze.   

Abstract

We describe experience with the use of mycophenolate mofetil (MMF) in neurological diseases. Although only small series of patients or case reports were described, MMF is promising in immune-mediated neuromuscular disorders. MMF has been used for the treatment of polymyositis, chronic inflammatory demyelinating polyradiculoneuropathy, and multifocal motor neuropathy. These studies showed that MMF is well tolerated and may be useful in some patients. MMF can be effective alone but mainly as an adjuvant therapy by reducing steroid requirements or the frequency of infusions of IVIg. MMF has also been tested alone as a single drug treatment or in combination with immunomodulatory drugs in multiple sclerosis in open surveillance trials or in phase II studies. None of these studies have been designed to demonstrate a clinical efficacy but preliminary results are very promising.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15803931     DOI: 10.1191/0961203305lu2117oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

1.  Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.

Authors:  M P J Garssen; R van Koningsveld; P A van Doorn; I S J Merkies; M Scheltens-de Boer; J A van Leusden; I N van Schaik; W H J P Linssen; F Visscher; A M Boon; C G Faber; J Meulstee; M J J Prick; L H van den Berg; H Franssen; J A P Hiel; P Y K van den Bergh; C J M Sindic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

3.  Mycophenolate mofetil in the treatment of uveitis in children.

Authors:  D Doycheva; C Deuter; N Stuebiger; S Biester; M Zierhut
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

4.  Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Authors:  Erika F Augustine; Christopher A Beck; Heather R Adams; Sara Defendorf; Amy Vierhile; Derek Timm; Jill M Weimer; Jonathan W Mink; Frederick J Marshall
Journal:  JIMD Rep       Date:  2018-06-20

5.  [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Authors:  Peter Rieckmann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

Review 6.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 7.  Oral disease-modifying treatments for multiple sclerosis: the story so far.

Authors:  Bernd C Kieseier; Heinz Wiendl
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.

Authors:  Rami Fakih; Marcelo Matiello; Tanuja Chitnis; James M Stankiewicz
Journal:  J Neurol       Date:  2018-09-10       Impact factor: 4.849

Review 9.  Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.

Authors:  Boel De Paepe; Jana Zschüntzsch
Journal:  Int J Mol Sci       Date:  2015-08-11       Impact factor: 5.923

10.  Premature senescence of placental decidua cells as a possible cause of miscarriage produced by mycophenolic acid.

Authors:  Paz de la Torre; Miguel Fernández-de la Torre; Ana I Flores
Journal:  J Biomed Sci       Date:  2021-01-04       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.